drugset
drugset / Trial / NCT05552196

A Study of Ponesimod in Healthy Adult Participants

NCT05552196 ↗

Phase 1 Completed 28 enrolled Janssen Pharmaceutica N.V., Belgium
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effect of steady-state carbamazepine (CBZ; a strong pregnane X receptor \[PXR\] agonist) on the pharmacokinetics (PK) of ponesimod following a gradual up-titration regimen in healthy adult participants.

Timeline

Start
2022-10-18
Primary completion
2023-03-05
Completion
2023-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule — Oral
Subject Ponesimod Small molecule — Oral

Indications

No indication recorded.